BioRestorative Therapies, Inc. announced that the first patient has been enrolled in the company’s Phase II clinical trial evaluating the safety and preliminary efficacy of BRTX-100, an autologous bone marrow-derived mesenchymal stem cell targeting chronic lumbar disc disease.
[BioRestorative Therapies, Inc. (GlobeNewswire, Inc.)]